Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

10.81
Delayed Data
As of 4:00pm ET
 +0.06 / +0.56%
Today’s Change
10.35
Today|||52-Week Range
38.50
-25.55%
Year-to-Date
Can This Pharma Stock Withstand the 'Trump Effect'?
Mar 25 / TheStreet.com - Paid Partner Content
Bill Ackman to Attend Ira Sohn Conference
Mar 23 / TheStreet.com - Paid Partner Content
Bill Ackman Finally Pukes: Beware of False Narratives
Mar 25 / GuruFocus News - Paid Partner Content
Troubled drug company pays CEO $63 million
Mar 23 / CNNMoney.com
Francis Chou Comments on Valeant
Mar 24 / GuruFocus News - Paid Partner Content
The 'Dogs' of Wall Street: Here's A Look at Some of the Worst Performing Stocks of Th...
Mar 23 / TheStreet.com - Paid Partner Content
Valeant: The End Of The Michael Pearson Era
Mar 23 / Investing Channel - Paid Partner Content
Saba Capital Management, L.P. Buys Allergan PLC, Alpine Total Dynamic Dividend Fund, ...
Mar 23 / GuruFocus News - Paid Partner Content
Pernix: An Investor's Rationale to Staying Long
Mar 23 / GuruFocus News - Paid Partner Content
Democrats Target Trump SEC Pick Clayton Over Conflicts
Mar 23 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close10.75
Today’s open10.69
Day’s range10.66 - 10.94
Volume8,907,420
Average volume (3 months)18,120,868
Market cap$3.7B
Dividend yield--
Data as of 4:00pm ET, 03/27/2017

Growth & Valuation

Earnings growth (last year)-716.47%
Earnings growth (this year)-28.43%
Earnings growth (next 5 years)+3.95%
Revenue growth (last year)-7.39%
P/E ratioNM
Price/Sales0.52
Price/Book1.19

Competitors

 Today’s
change
Today’s
% change
MDCOMedicines Co+0.22+0.43%
PTHNPatheon NV-0.07-0.27%
GLPGGalapagos NV+1.18+1.43%
CTLTCatalent Inc+0.42+1.50%
Data as of 4:02pm ET, 03/27/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)$0.92
Annual revenue (last year)$9.7B
Annual profit (last year)-$2.4B
Net profit margin-24.90%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Qubec

Forecasts


Search for Jobs